The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare relative bioavailability of the test formulation of
ropinirole hydrochloride 0.25 mg tablets (Manufactured and distributed by TEVA
Pharmaceuticals USA) with the already approved formulation REQUIP® (ropinirole hydrochloride)
0.25 mg tablets (GlaxoSmithKline) under fed conditions in healthy, adult subjects.